The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S13-S20 , October 2007

Clinical Experience with Daptomycin for the Treatment of Patients with Osteomyelitis

Portions of the results of this study were presented at the 43rd Annual Meeting of the Infectious Diseases Society of America; October 6–9, 2005; San Francisco, California. Abstract 401.

References 

  1. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?. Int J Infect Dis. 2005;9:127–138
  2. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369–379
  3. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis: why do antibiotics fail so often?. Postgrad Med J. 2000;76:479–483
  4. Cunha BA. Osteomyelitis in elderly patients. Clin Infect Dis. 2002;35:287–293
  5. Simor AE. Containing methicillin-resistant S aureus: surveillance, control, and treatment methods. Postgrad Med. 2001;110:43–48
  6. Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin Orthop Relat Res. 2002;38–44
  7. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994–1000
  8. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13:1159–1169
  9. Cubicin (daptomycin for injection). [prescribing information] Lexington, MA: Cubist Pharmaceuticals Inc; 2006;
  10. Mader JT, Adams K. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother. 1989;33:689–692
  11. Rouse MS, Piper KE, Jacobson M, Jacofsky DJ, Steckelberg JM, Platelet R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother. 2006;57:301–305
  12. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin. 2005;21:1923–1926
  13. Antony SJ, Hecht M, Angelos E, Stratton C. Clinical experience with daptomycin in patients with orthopedic-related infections. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America (IDSA) In: Alexandria, VA: Infections Diseases Society of America; 2005;p. 83–84Abstract 464
  14. Luu QN, Buxton TB, Nelson DR, Rissing JP. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur J Clin Microbiol Infect Dis. 1989;8:562–563
  15. Juthani-Mehta M, Vikram HR, Gorelick JL, Rappeport JM. Successful therapy of methicillin-resistant Staphylococcus aureus (MRSA) Vertebral Osteomyelitis (VOM) with Daptomycin. Presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA) In: Alexandria, VA: Infectious Diseases Society of America; 2003;p. 121;Abstract 298
  16. Rolston KVI, Segreti JA, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120(suppl 10A):S4–S5
  17. Rao N, Regalla DM. Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res. 2006;451:34–37
  18. Burns CA. Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy. Scand J Infect Dis. 2006;133–136
  19. Dretler R, Branch T. MRSA knee infection treated successfully with daptomycin after two failed prolonged high-dose courses of vancomycin. Infectious Diseases in Clinical Practice. 2005;327–329
  20. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis. 2005;37:572–578
  21. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992;36:2709–2714
  22. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665–4672
  23. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005;43:5384–5387
  24. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44:655–656
  25. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565–566
  26. Lewis JS, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664–1665
  27. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285–5287
  28. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2137–2145
  29. Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med. 2003;114:723–728
  30. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Clinical development and labeling of anti-infective drug products (Specific Infections). 2006;
  31. Mader JT, Norden C, Nelson JD, Calandra GB Infectious Diseases Society of America and the Food and Drug Administration. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Clin Infect Dis. 1992;15(suppl 1):S155–S161

 Please see the Author Disclosure section at the end of this article.

PII: S0002-9343(07)00660-2

doi: 10.1016/j.amjmed.2007.07.010

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S13-S20 , October 2007

Article Tools

* Image Usage & Resolution